(Health-NewsWire.Net, July 26, 2017 ) Otitis media (OM) is any inflammation of the middle ear the air-filled space behind the eardrum that contains the tiny vibrating bones of the ear. Symptoms include ear pain difficulty sleeping loss of balance fever headache and loss of appetite. Risk factors include age seasonal factors and exposure to tobacco smoke or high levels of air pollution. Treatment includes antibiotics and antipyrine.
Report Highlights
Pharmaceutical and Healthcare latest pipeline guide Otitis Media-Pipeline Review H2 2017 provides comprehensive information on the therapeutics under development for Otitis Media (Ear Nose Throat Disorders) complete with analysis by stage of development drug target mechanism of action (MoA) route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics its complete research and development history and latest news and press releases.
The Otitis Media (Ear Nose Throat Disorders) pipeline guide also reviews of key players involved in therapeutic development for Otitis Media and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes the molecules developed by Companies in Phase III Phase II Phase I Preclinical and Discovery stages are 2 3 2 3 and 3 respectively. Similarly the Universities portfolio in Preclinical stages comprises 1 molecules respectively.
Otitis Media (Ear Nose Throat Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Publisher's proprietary databases company/university websites clinical trial registries conferences SEC filings investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
- The pipeline guide provides a snapshot of the global therapeutic landscape of Otitis Media (Ear Nose Throat Disorders) . - The pipeline guide reviews pipeline therapeutics for Otitis Media (Ear Nose Throat Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources. - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. - The pipeline guide features descriptive drug profiles for the pipeline products which comprise product description descriptive licensing and collaboration details R&D brief MoA & other developmental activities. - The pipeline guide reviews key companies involved in Otitis Media (Ear Nose Throat Disorders) therapeutics and enlists all their major and minor projects. - The pipeline guide evaluates Otitis Media (Ear Nose Throat Disorders) therapeutics based on mechanism of action (MoA) drug target route of administration (RoA) and molecule type. - The pipeline guide encapsulates all the dormant and discontinued pipeline projects. - The pipeline guide reviews latest news related to pipeline therapeutics for Otitis Media (Ear Nose Throat Disorders)
- Procure strategically important competitor information analysis and insights to formulate effective R&D strategies. - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. - Find and recognize significant and varied types of therapeutics under development for Otitis Media (Ear Nose Throat Disorders) . - Classify potential new clients or partners in the target demographic. - Develop tactical initiatives by understanding the focus areas of leading companies. - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics. - Formulate corrective measures for pipeline projects by understanding Otitis Media (Ear Nose Throat Disorders) pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Key Company profiles ContraFect Corp GlaxoSmithKline Plc Lee's Pharmaceutical Holdings Ltd Madam Therapeutics BV Merck & Co Inc MerLion Pharmaceuticals Pte Ltd Novus Therapeutics Inc Otonomy Inc Yuhan Corp
List of Tables Number of Products under Development for Otitis Media H2 2017 Number of Products under Development by Companies H2 2017 Number of Products under Development by Universities/Institutes H2 2017 Products under Development by Companies H2 2017 Products under Development by Universities/Institutes H2 2017 Number of Products by Stage and Target H2 2017 Number of Products by Stage and Mechanism of Action H2 2017 Number of Products by Stage and Route of Administration H2 2017 Number of Products by Stage and Molecule Type H2 2017 Otitis Media-Pipeline by ContraFect Corp H2 2017 Otitis Media-Pipeline by GlaxoSmithKline Plc H2 2017 Otitis Media-Pipeline by Lee's Pharmaceutical Holdings Ltd H2 2017 Otitis Media-Pipeline by Madam Therapeutics BV H2 2017 Otitis Media-Pipeline by Merck & Co Inc H2 2017 Otitis Media-Pipeline by MerLion Pharmaceuticals Pte Ltd H2 2017 Otitis Media-Pipeline by Novus Therapeutics Inc H2 2017 Otitis Media-Pipeline by Otonomy Inc H2 2017 Otitis Media-Pipeline by Yuhan Corp H2 2017 Otitis Media-Dormant Projects H2 2017